GlobeNewswire

Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
21/09/2026
Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability Findings support continued [...]
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
21/09/2026
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile- - First global regulatory approval of obicetrapib [...]
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
21/09/2026
Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage [...]
STATLIA MATRIX MP Sets New Standard for Multiplex Assay Analysis and QC Automation
21/09/2026
CARLSBAD, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Brendan Bioanalytics has released STATLIA MATRIX MP, a powerful data analysis enterprise software system designed to improve the accuracy, reliability, and efficiency [...]
Z Optics Presents Six-Month Clinical Results for the Z+ Virtual Aperture IOL at ESCRS 2026
21/09/2026
Data presented by Dr. Francisco Sánchez León in London show reliably good uncorrected vision at distance, intermediate and near, in daylight and in low light, with no serious adverse events and every patient free of [...]
Novo Nordisk A/S - share repurchase programme
21/09/2026
Bagsværd, Denmark, 21 September 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy
21/09/2026
ALK today announced the appointment of Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (CPPS), effective 1 October 2026. Tina succeeds Jacob Glenting, who headed CPPS before [...]
Highlights to be presented at Novo’s Capital Markets Day 2026
21/09/2026
Bagsværd, Denmark, 21 September 2026 – Novo Nordisk is today hosting a Capital Markets Day (CMD) in London, where the company is providing an update to its Corporate strategy and strategic ambitions for 2030 1 . During [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
21/09/2026
COPENHAGEN, Denmark, September 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Beacon Therapeutics Reports Positive Topline Data from the Pivotal VISTA Trial of Laru-zova for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
21/09/2026
VISTA met its FDA-endorsed primary endpoint, demonstrating statistically significant low luminance visual acuity (LLVA) responder rates at Month 12 compared to the untreated control group A statistically significant [...]
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
21/09/2026
Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, [...]
SodaPeak Launch 2026: Effective Formula For Men Health Supports Men's Virility and vitality. Read Soda Peak Gummies Supplement Facts & Ingredients Highlights.
20/09/2026
Soda Peak Gummies introduces a natural vitality formula for men, featuring SodaPeak with selected botanical ingredients, supplement facts, and a multi-ingredient blend designed for everyday men’s wellness and vitality [...]
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
20/09/2026
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling study Primary endpoint and the key secondary endpoint were met [...]
NorahLux Launches Red Light Therapy Research Hub With Access to 10,000+ Photobiomodulation Studies
20/09/2026
Interactive research explorer helps users search scientific literature by condition, study type, light source and other criteria DEURNE, Netherlands, Sept. 19, 2026 (GLOBE NEWSWIRE) -- NorahLux has launched the Red [...]
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
18/09/2026
SAN CARLOS, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel [...]
Johns Hopkins USFHP is One of the Highest-Rated Health Plans in the Nation
18/09/2026
TRICARE Prime® Option Earns 4.5/5 in NCQA’s 2026 Ratings HANOVER, Md., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Johns Hopkins US Family Health Plan (USFHP) was recognized with an overall rating of 4.5 out of 5 in the National [...]
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
18/09/2026
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tardive dyskinesia (TD [...]
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
18/09/2026
New findings show favorable treatment continuity for UZEDY compared to other long-acting injectables in schizophrenia, as well as oral antipsychotics in bipolar I disorder (BD-I) The new real-world data also show that [...]
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
18/09/2026
In a post hoc analysis of the open-label safety stage of the Phase 3 SOLARIS trial, more than half of participants receiving TEV-'749 achieved stabilization, few relapsed and more than one-fifth of participants [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum